Raymond Debbane, Director at LEXICON PHARMACEUTICALS, INC. (LXRX), bought 2,000,000 shares at $1.03 ($2.2M) on 2023-10-12, disclosed to the SEC on 2023-10-12.
Open-market purchase of $2.2M LXRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.14 | 508,306 | $579K | 26.3% |
| 2 | $1.14 | 508,306 | $579K | 26.3% |
| 3 | $1.08 | 342,874 | $370K | 16.8% |
| 4 | $1.08 | 342,874 | $370K | 16.8% |
| 5 | $1.03 | 148,820 | $153K | 6.9% |
| 6 | $1.03 | 148,820 |
| $153K |
| 6.9% |
| Total | $1.10 avg | 2,000,000 | $2.2M | 100% |
| Filing → |
| LXRX | BUY | 2026-02-23 | $220K | — | Filing → |
| LXRX | BUY | 2026-02-18 | $353K | — | Filing → |
| WW | BUY | 2022-11-15 | $641K | — | Filing → |